Achillion Pharmaceuticals Культура компании

Dr. David Apelian, M.D., Ph.D., MBA,was the Chief Medical Officer and Executive Vice President of Achillion Pharmaceuticals, Inc. since May 28, 2013 until December 28, 2017. Dr. Apelian leads the Achillion rare disease development program for novel small-molecule complement factor D inhibitors for alternative pathway-mediated diseases. He was responsible for creating portfolio strategy and managing the Achillion 's clinical development programs with a focus on hepatitis C. He was instrumental in securing a partnership between Achillion and J&J, which resulted in a $225 million equity upfront payment and the potential for over $900 million in milestones. His clinical development and regulatory experience spans 17 years in all phases of development ranging from discovery to registration, across multiple therapeutic areas including GI, hepatology, immuno-oncology infectious diseases and rare diseases. He served as Chief Medical Officer at GlobeImmune, Inc. since January 2005 until 2013. He served as the Senior Vice President of Research & Development at GlobeImmune, Inc. since December 2008. He was responsible for clinical development, regulatory affairs, clinical immunology, development of companion diagnostics, as well as target discovery and preclinical research. He served as Vice President of Clinical Development and Regulatory Affairs at GlobeImmune, Inc. from January 2005 to December 2008. Dr. Apelian joined GlobeImmune from Bristol-Myers Squibb, where he served as a Clinical Director in the Department of Clinical Design and Evaluation/Infectious Diseases Group and was Medical Leader for clinical development for the NDA filing of entecavir for chronic HBV. Prior to, he served as Clinical Director in the Department of Hepatology/Gastroenterology at Schering Plough, coordinating a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic hepatitis C viral infection (HCV). He has been Director of Eiger BioPharmaceuticals, Inc. since June 14, 2017. He completed residency training in pediatrics at New York Hospital, Cornell Medical Center and is board certified in Pediatrics. Dr. Apelian received his Ph.D. in Biochemistry from Rutgers University, his M.D. from the University of Medicine and Dentistry of New Jersey and an M.B.A. from Quinnipiac University. He earned a B.A. in Biochemistry from Rutgers University.

Ms. Mary Kay Fenton serves as the Chief Financial Officer at Achillion Pharmaceuticals, Inc. Ms. Fenton has been an Executive Vice President of Achillion Pharmaceuticals, Inc. since March 06, 2014. She served as a Senior Vice President of Achillion Pharmaceuticals, Inc. from 2010 to March 06, 2014 and also served as its Vice President until 2010. She served as Vice President of Finance & Administration at Achillion Pharmaceuticals, Inc. She has led Achillion Pharmaceuticals Inc.'s financial function since October 2000. From 1991 to 2000, She held various positions within the Technology Industry Group at PricewaterhouseCoopers LLP, most recently as Senior Manager responsible for the life sciences practice in Connecticut. Prior to 1991, Ms. Fenton was an economic development associate in the nonprofit sector. She holds an M.B.A. degree in Finance from the Graduate School of Business at the University of Connecticut and an A.B in economics from the College of the Holy Cross. Ms. Fenton is a certified public accountant.

Mr. Joseph Truitt, also known as Joe, has been the Chief Operating Officer at Achillion Pharmaceuticals, Inc. since September 11, 2017 and served as its Chief Commercial Officer and an Executive Vice President of Business Development from January 2009 to September 11, 2017 and from March 06, 2014 to September 11, 2017 respectively. Mr. Truitt served as Senior Vice President of Business Development at Achillion Pharmaceuticals, Inc. from February 03, 2010 to March 06, 2014. He has over 15 years experience in pharmaceutical sales and marketing and served various senior management positions during his successful career. Mr. Truitti served as Business Consultant of CD Diagnostics, LLC. (AKA CD Diagnostics, Inc.). He served as Vice President of Business Development at Achillion Pharmaceuticals, Inc. since January 2009 and served as its Vice President until February 03, 2012. He served as Vice President of Business Development & Product Strategy at Lev Pharmaceuticals Inc. since November 2007. He served as Vice President of Sales and Marketing at Lev Pharmaceuticals Inc. from August 2006 to November 2007. He was responsible for building the sales, marketing and reimbursement team in anticipation of the launch of Lev Pharmaceuticals Inc.'s lead product candidate, C1-inhibitor for the treatment of hereditary angioedema ('HAE'), in Phase III clinical trials. At Johnson & Johnson, he served as Vice President of Sales and Operations and directed OraPharma's commercial operations and had P&L responsibility for sales, operations and national accounts. He built the sales management team at OraPharma Inc., and led the successful launch of OraPharma Inc.'s flagship product, Arestin(R). Mr. Truitt has a BS degree in Marketing from LaSalle University and an MBA degree from St. Joseph's University Haub School of Business.

Martha Manning serves as the Executive Vice President, General Counsel and Corporate Secretary of Achillion Pharmaceuticals, Inc.. Martha started at Achillion Pharmaceuticals, Inc. in February of 2016. Martha currently resides in Greater Philadelphia Area.

Mary Fenton serves as the Executive Vice President & Chief Financial Officer of Achillion Pharmaceuticals, Inc.. Mary started at Achillion Pharmaceuticals, Inc. in October of 2000. Mary currently resides in Greater New York City Area.

Daniel Kennedy serves as the Exec Director, Business Development of Achillion Pharmaceuticals, Inc.. Daniel started at Achillion Pharmaceuticals, Inc. in October of 2018. Daniel currently resides in the Greater Philadelphia Area.

Paul Firuta serves as the Chief Operating Officer of Achillion Pharmaceuticals, Inc.. Paul started at Achillion Pharmaceuticals, Inc. in September of 2018. Paul currently resides in the Greater Philadelphia Area.

John Viel serves as the Executive Director-Medical Affairs of Achillion Pharmaceuticals, Inc.. John started at Achillion Pharmaceuticals, Inc. in November of 2017. John currently resides in the Rockford, Illinois Area.

James Hui serves as the Executive Director, Clinical Pharmacology of Achillion Pharmaceuticals, Inc.. James started at Achillion Pharmaceuticals, Inc. in April of 2012. James currently resides in the Greater New York City Area.